Considerations for CPX-351 in Acute Myeloid Leukemia

2 vistas
administrator
administrator
07/04/23

Expert panelists Eunice Wang, MD; Harry Erba, MD, PhD; Alexander E. Perl, MD; and Jorge E. Cortes, MD, identify important considerations when treating acute myeloid leukemia with CPX-351, such as its toxicity profile and patient stratification.

  • categoría

Mostrar más

0 Comentarios Ordenar por

No se encontraron comentarios

Comentarios de Facebook

Hasta la próxima